GO:0010887 negative regulation of cholesterol storage: Lipid Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010887 (negative regulation of cholesterol storage) describes any biological process that decreases the rate or extent of intracellular cholesterol accumulation, counterbalancing cholesterol esterification and lipid droplet sequestration.
• The term is a biological_process branch of the Gene Ontology and is mechanistically linked to cholesterol trafficking, esterification by SOAT1/ACAT1, and reverse cholesterol transport.
• Key molecular players include SOAT1, ABCA1, NR1H2/NR1H3 (LXRbeta/LXRalpha), PPARG, STAR, and endolysosomal trafficking regulators such as NPC1 and NPC2.
• Dysregulation of this process contributes to atherosclerosis, clear cell renal cell carcinoma resistance, mammary tumor invasion, and sphingolipid storage disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes that negatively regulate cholesterol storage.
• Integrating lipidomics, transcriptomics, and imaging with CRISPR screening provides publication-grade evidence for GO:0010887 mechanisms.
Description
Cholesterol is an essential sterol that must be tightly controlled because its excess accumulation in cells and tissues drives metabolic and cardiovascular pathology. The Gene Ontology term GO:0010887, negative regulation of cholesterol storage, captures the biological processes that decrease the rate or extent of cholesterol storage, defined as the accumulation and maintenance of cholest-5-en-3 beta-ol within cells or tissues. This term is distinct from cholesterol biosynthesis or efflux alone because it specifically addresses the storage pool, including esterified cholesterol held in lipid droplets and endolysosomal compartments. Researchers study GO:0010887 because shifting the balance between cholesterol storage and mobilization has direct consequences for diseases such as atherosclerosis, cancer, and lysosomal storage disorders. For example, fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion, illustrating how negative regulation of storage can be co-opted by cancer cells. Similarly, STAT2/SLC27A3/PINK1-mediated mitophagy remodeling of lipid metabolism contributes to pazopanib resistance in clear cell renal cell carcinoma, linking storage regulation to therapeutic response. Mechanistically, negative regulation of cholesterol storage intersects with phosphatidylcholine-dependent cholesterol transport, START-domain-mediated trafficking in steroidogenic cells, and reverse cholesterol transport through PPARgamma-LXRalpha/beta-ABCA1 signaling. Understanding these pathways at the Gene Ontology level helps researchers design CRISPR models that test causality rather than correlation.
negative regulation of cholesterol storage At A Glance
| GO ID | GO:0010887 |
|---|---|
| GO term | negative regulation of cholesterol storage |
| Ontology | biological_process |
| Synonym | negative regulation of cholesterol sequestration |
| Definition | Any process that decreases the rate or extent of cholesterol storage, where cholesterol storage is the accumulation and maintenance of cholesterol, cholest-5-en-3 beta-ol, in cells or tissues. |
| Major function | Limits intracellular cholesterol accumulation by modulating esterification, trafficking, and efflux pathways. |
| Related processes | Cholesterol esterification, reverse cholesterol transport, endocytic trafficking, mitophagy-associated lipid remodeling. |
| Representative regulators | SOAT1, ABCA1, NR1H2/NR1H3, PPARG, STAR, NPC1/NPC2. |
| Disease relevance | Atherosclerosis, clear cell renal cell carcinoma, mammary tumor invasion, sphingolipid storage diseases. |
What Is GO:0010887?
GO:0010887, negative regulation of cholesterol storage, is a biological_process term defined as any process that decreases the rate or extent of cholesterol storage. Cholesterol storage itself is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. The synonym negative regulation of cholesterol sequestration is also used. In practice, this term covers molecular events that reduce the size, number, or turnover of intracellular cholesterol pools, including esterified cholesterol in lipid droplets and cholesterol retained in endolysosomal compartments.
Why Is negative regulation of cholesterol storage Important in Cell Biology?
Negative regulation of cholesterol storage is important because cholesterol overload is a shared feature of cardiovascular disease, cancer progression, and lysosomal storage disorders. The term provides a controlled vocabulary for annotating genes that reduce storage, enabling reproducible comparisons across transcriptomic, lipidomic, and CRISPR screening datasets. Because cholesterol is the precursor of bile acids and steroid hormones, its storage must be balanced against biosynthetic demand, and disruption of this balance has measurable physiological consequences.
• Provides a Gene Ontology framework for annotating genes that reduce intracellular cholesterol accumulation.
• Links cholesterol esterification by SOAT1 to cancer cell invasion and therapeutic resistance.
• Connects reverse cholesterol transport pathways such as PPARgamma-LXRalpha/beta-ABCA1 to atherosclerosis protection.
• Explains how endocytic trafficking defects cause cholesterol sequestration in sphingolipid storage diseases.
• Supports interpretation of lipidomics and transcriptomics data in metabolic and cardiovascular research.
• Guides CRISPR knockout and overexpression experiments that test causal roles of storage regulators.
• Helps identify biomarkers of pazopanib resistance in clear cell renal cell carcinoma.
• Informs therapeutic strategies targeting cholesterol storage in tumors and atherosclerotic plaques.
What Happens During negative regulation of cholesterol storage?
Sensing cholesterol excess and initiating negative regulation
In simple terms: Cells first notice when cholesterol builds up, then switch on processes that reduce storage.
Negative regulation of cholesterol storage begins with sensing of excess sterol, which can occur through endolysosomal cholesterol trafficking and lipid droplet dynamics. Phosphatidylcholine availability influences the cholesterol transport machinery, and perturbations in this lipid environment alter how cholesterol is distributed between membranes and storage pools. In steroidogenic cells, START domain proteins mediate intracellular cholesterol trafficking, providing a route by which storage can be modulated. These sensing and trafficking steps set the stage for downstream negative regulation.
Reducing cholesterol esterification and lipid droplet sequestration
In simple terms: The cell lowers the amount of cholesterol that gets packaged into storage droplets.
A central mechanism of negative regulation is reduced esterification of cholesterol and decreased sequestration into lipid droplets. Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner, demonstrating that receptor tyrosine kinase pathways can control the esterification step that feeds storage. When SOAT1 activity or expression is altered, the balance between free and esterified cholesterol shifts, changing the storage pool. This step is therefore a key node for experimental manipulation of GO:0010887.
Promoting cholesterol mobilization and reverse transport
In simple terms: Instead of storing cholesterol, the cell moves it out or converts it for other uses.
Negative regulation of storage also involves mobilization of cholesterol toward efflux and reverse transport. The PPARgamma-LXRalpha/beta-ABCA1 pathway promotes reverse cholesterol transport, reducing the retention of cholesterol in peripheral compartments. Activation of this axis increases ABCA1-mediated efflux and limits storage accumulation. Inflammatory cytokines regulate high-density lipoprotein metabolism, further linking systemic lipid transport to cellular storage balance. These pathways provide mechanistic entry points for interventions that enhance negative regulation.
Coupling storage regulation to mitophagy and organelle remodeling
In simple terms: Cells can remodel their energy and lipid organelles to change how much cholesterol they keep.
Mitophagy and organelle remodeling can be coupled to lipid metabolism, as shown by STAT2/SLC27A3/PINK1-mediated mitophagy remodeling lipid metabolism in clear cell renal cell carcinoma. This axis contributes to pazopanib resistance, indicating that negative regulation of cholesterol storage is embedded in stress-response and drug-resistance networks. Endocytic trafficking of glycosphingolipids also influences cholesterol distribution in sphingolipid storage diseases, where impaired trafficking leads to sequestration. Together, these findings show that storage regulation is integrated with mitochondrial quality control and endolysosomal function.
Transcriptional and post-transcriptional control of storage regulators
In simple terms: The cell tunes the amounts of storage-related proteins up or down.
Transcriptional programs such as LXRalpha/beta and PPARgamma control genes involved in cholesterol efflux and transport, thereby reducing storage. Post-transcriptional and signaling inputs, including inflammatory cytokine signaling, further modulate high-density lipoprotein and cholesterol handling. In steroidogenic cells, START domain proteins govern cholesterol movement, and their regulation affects the storage pool. These layered controls ensure that negative regulation of cholesterol storage can be adjusted to physiological demand.
Key Genes Involved in GO:0010887 negative regulation of cholesterol storage
The following genes and proteins have documented roles in pathways that negatively regulate cholesterol storage, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOAT1 | Catalyzes cholesterol esterification, controlling lipid droplet storage | FGFR signaling modulates storage in a SOAT1-dependent manner in mammary tumor invasion |
| ABCA1 | Mediates cholesterol efflux as part of reverse cholesterol transport | PPARgamma-LXRalpha/beta-ABCA1 pathway inhibits atherosclerosis |
| NR1H2 | LXRbeta nuclear receptor regulating cholesterol transport genes | Part of the LXRalpha/beta arm of reverse cholesterol transport |
| NR1H3 | LXRalpha nuclear receptor regulating cholesterol efflux and storage | Coordinates transcriptional control of cholesterol handling |
| PPARG | Nuclear receptor upstream of LXR-ABCA1 reverse transport | QiShenYiQi pill inhibits atherosclerosis via PPARgamma-LXRalpha/beta-ABCA1 |
| STAR | START domain protein trafficking cholesterol in steroidogenic cells | Controls intracellular cholesterol movement and storage balance |
| NPC1 | Endolysosomal cholesterol trafficking protein | Defects cause cholesterol sequestration in storage disorders |
| NPC2 | Lysosomal cholesterol transfer protein | Works with NPC1 in endocytic cholesterol trafficking |
| PINK1 | Mitophagy kinase linked to lipid metabolism remodeling | STAT2/SLC27A3/PINK1 mitophagy axis in ccRCC pazopanib resistance |
| STAT2 | Transcription factor in interferon and lipid metabolic remodeling | Part of the STAT2/SLC27A3/PINK1 axis |
| SLC27A3 | Fatty acid transport protein family member | Component of the mitophagy-lipid metabolism axis |
| APOA1 | Major HDL apolipoprotein enabling reverse cholesterol transport | Inflammatory cytokines regulate HDL and cholesterol handling |
| TNF | Inflammatory cytokine modulating HDL and lipid metabolism | Links immune dysfunction to cardiovascular disease |
| IL6 | Inflammatory cytokine affecting HDL metabolism | Establishes links between inflammation and cholesterol transport |
| GM2A | GM2 ganglioside activator involved in sphingolipid trafficking | Gangliosidoses illustrate storage and trafficking defects |
| HEXB | Beta-hexosaminidase subunit in ganglioside catabolism | Ganglioside storage diseases affect cholesterol trafficking |
| PCTP | Phosphatidylcholine transfer protein supporting cholesterol transport | Phosphatidylcholine greases the cholesterol transport machinery |
How Is negative regulation of cholesterol storage Regulated?
Negative regulation of cholesterol storage is controlled at multiple levels. Transcriptionally, the PPARgamma-LXRalpha/beta-ABCA1 axis promotes reverse cholesterol transport and limits cholesterol retention. Inflammatory cytokines such as TNF and IL6 regulate high-density lipoprotein metabolism, connecting immune signaling to cholesterol handling. At the protein and organelle level, mitophagy remodeling through STAT2/SLC27A3/PINK1 alters lipid metabolism and drug resistance in clear cell renal cell carcinoma. Endocytic trafficking pathways for glycosphingolipids influence cholesterol distribution, and their disruption leads to sequestration in storage diseases. Phosphatidylcholine availability and START-domain-mediated trafficking further tune the storage pool in a cell-type-specific manner.
negative regulation of cholesterol storage and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOAT1 | Mammary tumor invasion via cholesterol storage modulation | SOAT1 knockout and point-mutation mammary tumor cell lines |
| STAT2 | Clear cell renal cell carcinoma pazopanib resistance | STAT2 knockout ccRCC cells with mitophagy readouts |
| ABCA1 | Atherosclerosis and reverse cholesterol transport | ABCA1 overexpression and knockout macrophage models |
| NPC1 | Sphingolipid storage disease with cholesterol sequestration | NPC1 knockout fibroblasts and endocytic trafficking assays |
| STAR | Steroidogenic cholesterol trafficking disorders | STAR knockout steroidogenic cell models |
Cancer progression and therapeutic resistance
Negative regulation of cholesterol storage is relevant to cancer because tumor cells reprogram lipid metabolism to support invasion and survival. FGFR signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion, showing that storage control can be oncogenic. In clear cell renal cell carcinoma, STAT2/SLC27A3/PINK1-mediated mitophagy remodeling of lipid metabolism contributes to pazopanib resistance, linking storage regulation to tyrosine kinase inhibitor response. These findings suggest that genes annotated to GO:0010887 may serve as biomarkers or therapeutic targets in oncology.
Atherosclerosis and cardiovascular disease
Atherosclerosis is driven by cholesterol accumulation in arterial walls, and reverse cholesterol transport counteracts this process. The PPARgamma-LXRalpha/beta-ABCA1 pathway promotes reverse cholesterol transport and inhibits atherosclerosis in experimental models. Inflammatory cytokines regulate high-density lipoprotein metabolism, establishing links between immune dysfunction and cardiovascular disease. Therefore, enhancing negative regulation of cholesterol storage is a plausible strategy for plaque reduction.
Sphingolipid storage disorders and neurodegeneration
Endocytic trafficking of glycosphingolipids is disrupted in sphingolipid storage diseases, leading to cholesterol sequestration and cellular dysfunction. Gangliosides and gangliosidoses illustrate principles of molecular and metabolic pathogenesis in which lipid storage overload damages neurons. These disorders highlight how failure of negative regulation of cholesterol storage contributes to neurodegeneration.
Steroidogenic and metabolic disorders
In steroidogenic cells, START domain proteins mediate intracellular cholesterol trafficking, and their dysfunction can alter hormone synthesis and storage balance. Phosphatidylcholine availability affects the cholesterol transport machinery, so metabolic perturbations in phospholipid supply may indirectly impair negative regulation of storage. These mechanisms are relevant to endocrine and metabolic disease research.
From negative regulation of cholesterol storage-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase cholesterol storage? | CRISPR knockout cell line with lipidomics and imaging |
| Does a specific missense variant alter storage regulation? | CRISPR point-mutation knock-in isogenic line |
| Does tagging a regulator affect its localization and function? | Tagged knock-in with fluorescent or affinity tag |
| Does overexpression reduce cholesterol storage? | Stable overexpression cell line with cholesterol efflux assays |
| Which genes are required for negative regulation of storage? | Genome-wide CRISPR knockout library screening |
| How does mitophagy remodeling affect storage? | PINK1/STAT2 knockout and rescue models |
How to Study the negative regulation of cholesterol storage Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | Free and esterified cholesterol species | Quantifying storage changes after knockout |
| RNA-seq | Transcriptome and GO enrichment | Identifying storage-related gene programs |
| Fluorescence microscopy | Lipid droplet number and endolysosomal cholesterol | Visualizing sequestration defects |
| CRISPR knockout screening | Gene requirement for storage regulation | Discovery of novel regulators |
| Cholesterol efflux assay | ABCA1-mediated cholesterol export | Testing reverse transport activation |
| Western blot | Protein levels of SOAT1, ABCA1, STAR | Validating expression changes |
| Mitophagy flux assay | PINK1-dependent mitochondrial clearance | Linking mitophagy to lipid remodeling |
| Steroid hormone measurement | Downstream steroid output | Assessing steroidogenic cholesterol trafficking |
Lipidomics and cholesterol quantification
Mass spectrometry-based lipidomics and enzymatic cholesterol assays quantify free and esterified cholesterol pools, allowing direct measurement of storage changes after genetic perturbation. These methods are essential for validating GO:0010887 annotations in cell models.
Transcriptomics and pathway analysis
RNA sequencing followed by Gene Ontology enrichment can identify whether negative regulation of cholesterol storage is affected by a perturbation. Pathway analysis of PPARgamma-LXRalpha/beta-ABCA1 targets provides mechanistic context.
Imaging of lipid droplets and trafficking
Fluorescence imaging of lipid droplets and endolysosomal compartments reveals cholesterol sequestration and trafficking defects. These assays are particularly informative in sphingolipid storage disease models.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens combined with cholesterol storage readouts can nominate novel negative regulators. Hit validation using isogenic knockout and overexpression lines establishes causality.
How CRISPR Can Be Used to Study GO:0010887 negative regulation of cholesterol storage
Knockout
CRISPR knockout of candidate genes such as SOAT1, ABCA1, or STAT2 tests whether their loss increases cholesterol storage, providing causal evidence for GO:0010887 annotation. Knockout models are typically validated by lipidomics and imaging.
Point Mutation
Point-mutation knock-in can model disease-associated missense variants in storage regulators, revealing whether specific residues are required for negative regulation of cholesterol storage. Isogenic pairs control for background genetic variation.
Knock-in
Tagged knock-in of genes such as STAR or NPC1 enables tracking of protein localization and interaction with cholesterol trafficking machinery. This approach links molecular behavior to storage phenotypes.
Overexpression
Overexpression of ABCA1 or PPARG-pathway components can enhance reverse cholesterol transport and reduce storage, testing sufficiency for negative regulation. Overexpression models complement loss-of-function studies.
How EDITGENE Supports negative regulation of cholesterol storage Research
Researchers studying negative regulation of cholesterol storage-related genes often need to determine whether a candidate gene is causally involved in reducing cholesterol accumulation or is merely correlated with it. EDITGENE provides publication-ready CRISPR cell models and screening services that enable this causal testing across knockout, point-mutation, knock-in, and overexpression formats.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cholesterol storage research.
Frequently Asked Questions About negative regulation of cholesterol storage
What is GO:0010887 negative regulation of cholesterol storage?
GO:0010887 is a Gene Ontology biological_process term defined as any process that decreases the rate or extent of cholesterol storage, where cholesterol storage is the accumulation and maintenance of cholesterol, cholest-5-en-3 beta-ol, in cells or tissues.
What genes are involved in negative regulation of cholesterol storage?
Documented genes include SOAT1, ABCA1, NR1H2, NR1H3, PPARG, STAR, NPC1, NPC2, PINK1, STAT2, and SLC27A3, based on studies of cholesterol esterification, reverse transport, and mitophagy-linked lipid remodeling.
How is cholesterol storage negatively regulated in cells?
Cells reduce storage by limiting cholesterol esterification, promoting efflux through reverse cholesterol transport, and remodeling organelles such as mitochondria and endolysosomes.
Why is negative regulation of cholesterol storage important in cancer?
FGFR signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor invasion, and STAT2/SLC27A3/PINK1-mediated mitophagy remodeling contributes to pazopanib resistance in clear cell renal cell carcinoma.
How does reverse cholesterol transport reduce cholesterol storage?
The PPARgamma-LXRalpha/beta-ABCA1 pathway promotes reverse cholesterol transport, increasing cholesterol efflux and inhibiting atherosclerosis in experimental models.
What diseases are linked to defective cholesterol storage regulation?
Atherosclerosis, clear cell renal cell carcinoma, mammary tumor invasion, and sphingolipid storage diseases such as gangliosidoses are linked to altered cholesterol storage regulation.
What experimental models are used to study GO:0010887?
CRISPR knockout, point-mutation, knock-in, and overexpression cell lines combined with lipidomics, imaging, and transcriptomics are commonly used.
How does phosphatidylcholine affect cholesterol transport and storage?
Phosphatidylcholine availability influences the cholesterol transport machinery, and altering it can change how cholesterol is distributed between membranes and storage pools.
What role do START domain proteins play in cholesterol storage?
START domain proteins mediate intracellular cholesterol trafficking in steroidogenic cells, affecting the balance between cholesterol utilization and storage.
Can CRISPR screening identify new regulators of cholesterol storage?
Yes, pooled CRISPR knockout screens combined with cholesterol storage readouts can nominate novel negative regulators, which are then validated in isogenic models.
Conclusion
GO:0010887, negative regulation of cholesterol storage, provides a precise ontology framework for studying how cells limit cholesterol accumulation. The process integrates cholesterol esterification control, reverse cholesterol transport, endolysosomal trafficking, and mitophagy-linked lipid remodeling, with documented roles in cancer, atherosclerosis, and storage disorders. CRISPR-based causal models combined with lipidomics and transcriptomics are essential for moving from annotation to mechanism.
References
- 1. Lu D et al.. 2024. STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.. Research (Wash D C) 7:0539 PMID: 39600540
- 2. Lagace TA. 2015. Phosphatidylcholine: Greasing the Cholesterol Transport Machinery.. Lipid Insights 8(Suppl 1):65-73 PMID: 27081313
- 3. Pagano RE. 2003. Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases.. Philos Trans R Soc Lond B Biol Sci 358(1433):885-91 PMID: 12803922
- 4. Haas MJ et al.. 2010. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease.. Diabetes Metab Res Rev 26(2):90-9 PMID: 20047197
- 5. Tuokkola JE et al.. 2025. Fibroblast growth factor receptor signaling modulates cholesterol storage in a SOAT1-dependent manner to promote mammary tumor cell invasion.. Breast Cancer Res 27(1):132 PMID: 40665359
- 6. Strauss JF 3rd et al.. 2003. START domain proteins and the intracellular trafficking of cholesterol in steroidogenic cells.. Mol Cell Endocrinol 202(1-2):59-65 PMID: 12770731
- 7. Sandhoff K et al.. 2013. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis.. J Neurosci 33(25):10195-208 PMID: 23785136
- 8. Xie J et al.. 2023. QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway.. J Ethnopharmacol 315:116684 PMID: 37230281
